Leerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE